Novel Indicators of Transplant Outcomes for PhALL: Current Molecular-Relapse-Free Survival
Volume: 27, Issue: 9, Pages: 800.e1 - 800.e8
Published: Sep 1, 2021
Abstract
Molecular relapse after allogeneic hematopoietic cell transplantation (allo-HCT) has been thought to predict clinical relapse in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (PhALL). Tyrosine kinase inhibitor (TKI) administration after allo-HCT may dynamically change the status from molecular relapse to molecular remission, but these state changes cannot be accurately represented by conventional survival indicators...
Paper Details
Title
Novel Indicators of Transplant Outcomes for PhALL: Current Molecular-Relapse-Free Survival
Published Date
Sep 1, 2021
Volume
27
Issue
9
Pages
800.e1 - 800.e8
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History